回盛生物(300871) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was CNY 210,170,120.01, representing a 0.29% increase year-over-year, while the year-to-date revenue reached CNY 745,909,515.64, up 50.27% compared to the same period last year[4] - The net profit attributable to shareholders for Q3 2021 was CNY 18,400,670.22, a decrease of 58.54% year-over-year, with a year-to-date net profit of CNY 119,728,893.47, reflecting a 23.50% increase[4] - Basic earnings per share for Q3 2021 were CNY 0.11, down 65.63% year-over-year, while the year-to-date figure was CNY 0.72, a decrease of 4.00%[5] - Total operating revenue for the third quarter reached CNY 745.91 million, a significant increase of 50.4% compared to CNY 496.38 million in the same period last year[27] - Net profit for the period was CNY 119.73 million, representing a 23.5% increase from CNY 96.94 million in the previous year[28] - The total comprehensive income for the third quarter of 2021 was CNY 119,728,893.47, compared to CNY 96,943,862.66 in the same period last year, representing a year-over-year increase of approximately 23.5%[29] Assets and Liabilities - The company's total assets as of September 30, 2021, were CNY 1,975,021,786.44, an increase of 12.72% from the end of the previous year[5] - The company’s total liabilities increased to CNY 520.48 million, up 39.5% from CNY 373.08 million at the end of 2020[26] - Total current liabilities amount to CNY 338,671,606.52, with accounts payable at CNY 79,791,915.16 and short-term loans at CNY 63,000,000.00[38] - Total non-current liabilities are CNY 34,404,111.49, including lease liabilities of CNY 6,416,560.92 and deferred income of CNY 24,702,550.57[39] - Total liabilities amount to CNY 373,075,718.01, while total equity stands at CNY 1,379,150,114.50, resulting in total liabilities and equity of CNY 1,752,225,832.51[39] Cash Flow - Cash flow from operating activities for the year-to-date period was CNY 119,590,909.85, a significant increase of 176.42% compared to the same period last year[11] - Cash inflow from operating activities reached CNY 838,964,253.89, significantly higher than CNY 447,758,161.70 in the prior year, marking an increase of approximately 87%[31] - The net cash flow from operating activities was CNY 119,590,909.85, up from CNY 43,264,235.36 in the same period last year, indicating a growth of over 176%[32] - Cash flow from investment activities showed a net outflow of CNY 50,389,141.10, compared to a larger outflow of CNY 154,705,703.12 in the previous year, reflecting an improvement in investment cash flow[33] - The company’s cash balance at the end of the period was CNY 360,261,233.85, down from CNY 907,935,759.90 at the end of the previous year[34] Inventory and Costs - The company reported a 66.42% increase in inventory, amounting to CNY 211,793,551.36, due to increased sales scale and inventory buildup[10] - The company’s gross profit margin was impacted by a 65.99% increase in operating costs, which totaled CNY 513,723,814.54 due to increased sales volume[11] - Total operating costs amounted to CNY 616.45 million, up 60.1% from CNY 384.98 million year-over-year[27] Research and Development - Research and development expenses for Q3 2021 were CNY 28,118,387.31, representing a 78.29% increase year-over-year, indicating a focus on enhancing R&D capabilities[11] - Research and development expenses rose to CNY 28.12 million, a 78.5% increase from CNY 15.77 million in the previous year[27] Shareholder Information - Wuhan Huisheng Biotechnology Co., Ltd. reported that the total number of common shareholders at the end of the reporting period was 9,612[14] - The largest shareholder, Wuhan Tongsheng Investment Co., Ltd., holds 49.80% of shares, totaling 82,800,000 shares[14] - The top ten shareholders include several investment firms with significant stakes, such as Shenzhen Innovation Investment Group Co., Ltd. at 5.32% and Shenzhen Hongtu Biotechnology Venture Capital Co., Ltd. at 3.70%[14] - The total number of shares held by the top ten unrestricted shareholders amounts to 118,000,000 shares[15] - The company has a total of 82,800,000 shares under lock-up due to initial public offering restrictions, set to be released on August 24, 2023[17] Future Outlook - The company anticipates a decrease in overall demand for veterinary drug products due to the livestock industry's downturn[19] - The company plans to adjust the performance assessment indicators of the stock incentive plan in response to the changing industry competition[19] - The company plans to continue expanding its market presence and investing in new product development[24] - The company is in the process of issuing convertible bonds to unspecified investors, with the application approved by the Shenzhen Stock Exchange on August 19, 2021[20] - The company has initiated the process for issuing convertible bonds, pending regulatory approval[21] Other Information - The third quarter report has not been audited, indicating that the figures may be subject to change upon final review[40] - The company has implemented new leasing standards starting in 2021, which may affect future financial reporting[40] - The report does not provide specific user data or performance guidance for future quarters[41]